FDA, Zepbound and obstructive sleep apnea

Zepbound Gets FDA Approval to Treat Sleep Apnea
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA announced today.
FDA approves first-ever medication for obstructive sleep apnea
“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical Care at the FDA’s Center for Drug Evaluation and Research.
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.
FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to severe OSA in people with obesity.
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.
FDA approves new drug for sleep apnea
The drug is known as Zepbound and is the same as the chemical drug Tirzepatide. "See To Believe uncovers the forgotten, mind-blowing facts that will leave you questioning everything. Follow wild stories of mysterious creatures,
WISH-TV on MSN1h
Morning Checkup | Living with sleep apnea
Georgia, Notre Dame fans make Sugar Bowl decision as game is postponed over terror attack A Little Boy Found a Strange Stone on the Beach. Archaeologists Told Him It Was a Neanderthal's Hand Ax Tribe ...
Science Daily2d
Obstructive Sleep Apnea News
This is the first time breathing rhythms during ... Sleep Apnea Contributes to Dementia in Older Adults, Especially Women Oct. 31, 2024 — Sleep apnea, a common yet underdiagnosed sleep ...
Everyday Health5d
FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
ABP Live on MSN8h
Why A Kolkata Clinic Is Advocating for Insurance Coverage for Sleep Disorders
A sleep laboratory in Kolkata is campaigning to normalize insurance coverage for Obstructive Sleep Apnea (OSA), a common but ...
Sleep apnea? Neuro implants promise good night’s rest
WAKE-UP CALL: 104m Indians or 11% of the population suffer from obstructive sleep apnea, according to a 2023 AIIMS study ...
Health Beat: Sleep disorders in the Hispanic community
According to the Hispanic Community Health Study, 14% of Hispanic men and 6% of Hispanic women have sleep apnea. With so many ...